{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:58:00Z","timestamp":1784397480336,"version":"3.55.0"},"reference-count":60,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Mens Health"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>The ubiquitin-proteasome system (UPS) is intricately linked to the growth and metastasis of numerous types of cancer. However, current analysis on the function and impact of UPS in bladder cancer (BLCA) is still sparse. First, univariate Cox regression analysis was applied to screen survival-associated UPS-related genes (UPSGs). Then, based on the expression of survival-related UPSGs, BLCA patients were divided into three clusters through unsupervised cluster analysis, and the overall survival rate of Cluster 1 and Cluster 3 was higher than that of Cluster 2, but there was no survival difference between Cluster 1 and Cluster 3. Therefore, Cluster 1 + Cluster 3 (Cluster A) and Cluster 2 (Cluster B) were selected for subsequent analysis. The differentially expressed genes of the two clusters were predominantly enriched in signaling pathways such as the Calcium signaling pathway and Cytokine-cytokine receptor interaction. An immune microenvironment analysis revealed that Cluster B patients were characterized by highly infiltrated immunosuppressive cells (M2 macrophages and Tregs) as well as high expression of immune checkpoint genes (such as BTLA and CTLA4). Furthermore, Cluster B exhibited a higher TIDE score. Somatic mutations demonstrated that the mutation rate of Cluster B was higher than that of Cluster A. In addition, candidate drugs for two clusters of patients were predicted, with Lapatinib, Doramapimod, and SCH772984 may be potential drugs for Cluster A patients. Luminespib, Staurosporine, and Dasatinib may be more suitable for Cluster B patients. The study provides a reference for guiding the clinical treatment of BLCA patients.<\/jats:p>","DOI":"10.1177\/15579883251410519","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:17:16Z","timestamp":1767773836000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape"],"prefix":"10.1177","volume":"20","author":[{"given":"Guanyun","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Urology, Taizhou Municipal Hospital, Taizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Taizhou Municipal Hospital, Taizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Taizhou Municipal Hospital, Taizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8270-9711","authenticated-orcid":false,"given":"Tianxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Taizhou Boai Hospital, Taizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Augello G. Emma M. R. Cusimano A. Azzolina A. Mongiovi S. Puleio R. .\u2004.\u2004.Cervello M. (2019). Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. International Journal of Cancer 144(10) 2613\u20132624. https:\/\/doi.org\/10.1002\/ijc.31963","DOI":"10.1002\/ijc.31963"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Basak U. Sarkar T. Mukherjee S. Chakraborty S. Dutta A. Dutta S. .\u2004.\u2004.Sa G. (2023). Tumor-associated macrophages: An effective player of the tumor microenvironment. Frontiers in Immunology 14 Article 1295257. https:\/\/doi.org\/10.3389\/fimmu.2023.1295257","DOI":"10.3389\/fimmu.2023.1295257"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Batalha S. Ferreira S. Brito C. (2021). The peripheral immune landscape of breast cancer: Clinical findings and in vitro models for biomarker discovery. Cancers (Basel) 13(6) 1305. https:\/\/doi.org\/10.3390\/cancers13061305","DOI":"10.3390\/cancers13061305"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Bray F. Laversanne M. Sung H. Ferlay J. Siegel R. L. Soerjomataram I. Jemal A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3) 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Buss J. H. Begnini K. R. Bruinsmann F. A. Ceolin T. Sonego M. S. Pohlmann A. R. .\u2004.\u2004.Seixas F. K. (2019). Lapatinib-loaded nanocapsules enhances antitumoral effect in human bladder cancer cell. Frontiers in Oncology 9 Article 203. https:\/\/doi.org\/10.3389\/fonc.2019.00203","DOI":"10.3389\/fonc.2019.00203"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Cassetta L. Fragkogianni S. Sims A. H. Swierczak A. Forrester L. M. Zhang H. .\u2004.\u2004.Pollard J. W. (2019). Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming biomarkers and therapeutic targets. Cancer Cell 35(4) 588\u2013602.e510. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.009","DOI":"10.1016\/j.ccell.2019.02.009"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Cetin G. Klafack S. Studencka-Turski M. Kruger E. Ebstein F. (2021). The ubiquitin-proteasome system in immune cells. Biomolecules 11(1) 60. https:\/\/doi.org\/10.3390\/biom11010060","DOI":"10.3390\/biom11010060"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Chang N. Lee H. W. Lim J. E. Jeong D. E. Song H. J. Kim S. .\u2004.\u2004.Jeon H. G. (2016). Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion. Oncotarget 7(32) 51626\u201351639. https:\/\/doi.org\/10.18632\/oncotarget.10539","DOI":"10.18632\/oncotarget.10539"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Chen S. Jiang L. Zheng X. Shao J. Wang T. Zhang E. .\u2004.\u2004.Zheng J. (2021). Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer. Cancer Science 112(7) 2905\u20132914. https:\/\/doi.org\/10.1111\/cas.14927","DOI":"10.1111\/cas.14927"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Chen X. Lin X. Pang G. Deng J. Xie Q. Zhang Z. (2021). Significance of KDM6A mutation in bladder cancer immune escape. BMC Cancer 21(1) Article 635. https:\/\/doi.org\/10.1186\/s12885-021-08372-9","DOI":"10.1186\/s12885-021-08372-9"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Chevrier S. Levine J. H. Zanotelli V. R. T. Silina K. Schulz D. Bacac M. .\u2004.\u2004.Bodenmiller B. (2017). An immune atlas of clear cell renal cell carcinoma. Cell 169(4) 736\u2013749.e718. https:\/\/doi.org\/10.1016\/j.cell.2017.04.016","DOI":"10.1016\/j.cell.2017.04.016"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Chung R. McKiernan J. Arpaia N. Marabelle A. Rouanne M. (2023). Neo-adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer 187 58\u201364. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.037","DOI":"10.1016\/j.ejca.2023.03.037"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Colberg L. Cammann C. Greinacher A. Seifert U. (2020). Structure and function of the ubiquitin-proteasome system in platelets. Journal of Thrombosis and Haemostasis 18(4) 771\u2013780. https:\/\/doi.org\/10.1111\/jth.14730","DOI":"10.1111\/jth.14730"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Cuende J. Lienart S. Dedobbeleer O. van der Woning B. De Boeck G. Stockis J. .\u2004.\u2004.Lucas S. (2015). Monoclonal antibodies against GARP\/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine 7(284) 284ra256. https:\/\/doi.org\/10.1126\/scitranslmed.aaa1983","DOI":"10.1126\/scitranslmed.aaa1983"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Dagar G. Kumar R. Yadav K. K. Singh M. Pandita T. K. (2023). Ubiquitination and deubiquitination: Implications on cancer therapy. Biochimica et Biophysica Acta\u2014Gene Regulatory Mechanisms 1866(4) 194979. https:\/\/doi.org\/10.1016\/j.bbagrm.2023.194979","DOI":"10.1016\/j.bbagrm.2023.194979"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Dolatabadi B. Peymani M. Rouhi L. Salehzadeh A. Hushmandi K. Hashemi M. (2024). The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2. Molecular and Cellular Probes 78 101985. https:\/\/doi.org\/10.1016\/j.mcp.2024.101985","DOI":"10.1016\/j.mcp.2024.101985"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Epp-Ducharme B. Dunne M. Fan L. Evans J. C. Ahmed L. Bannigan P. Allen C. (2021). Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Scientific Reports 11(1) 11103. https:\/\/doi.org\/10.1038\/s41598-021-90585-w","DOI":"10.1038\/s41598-021-90585-w"},{"key":"e_1_3_2_19_1","unstructured":"Genomic Data Commons Data Portal. (n.d.). https:\/\/portal.gdc.cancer.gov\/"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Han X. Chen J. Wang J. Xu J. Liu Y. (2022). TTN mutations predict a poor prognosis in patients with thyroid cancer. Bioscience Reports 42(7) BSR20221168. https:\/\/doi.org\/10.1042\/BSR20221168","DOI":"10.1042\/BSR20221168"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Heo S. K. Noh E. K. Kim J. Y. Jeong Y. K. Jo J. C. Choi Y. .\u2004.\u2004.Kim H. (2017). Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Scientific Reports 7(1) 15278. https:\/\/doi.org\/10.1038\/s41598-017-15492-5","DOI":"10.1038\/s41598-017-15492-5"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Ho S. R. Lee Y. C. Ittmann M. M. Lin F. T. Chan K. S. Lin W. C. (2021). RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Letters 520 344\u2013360. https:\/\/doi.org\/10.1016\/j.canlet.2021.08.008","DOI":"10.1016\/j.canlet.2021.08.008"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Ho W. J. Jaffee E. M. Zheng L. (2020). The tumour microenvironment in pancreatic cancer\u2014Clinical challenges and opportunities. Nature Reviews Clinical Oncology 17(9) 527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5","DOI":"10.1038\/s41571-020-0363-5"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Jubber I. Ong S. Bukavina L. Black P. C. Comperat E. Kamat A. M. .\u2004.\u2004.Cumberbatch M. G. (2023). Epidemiology of bladder cancer in 2023: A systematic review of risk factors. European Urology 84(2) 176\u2013190. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.029","DOI":"10.1016\/j.eururo.2023.03.029"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Kamat A. M. Hahn N. M. Efstathiou J. A. Lerner S. P. Malmstrom P. U. Choi W. .\u2004.\u2004.Kassouf W. (2016). Bladder cancer. The Lancet 388(10061) 2796\u20132810. https:\/\/doi.org\/10.1016\/S0140-6736(16)30512-8","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Lenis A. T. Lec P. M. Chamie K. Mshs M. D. (2020). Bladder cancer: A review. Journal of the American Medical Association 324(19) 1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","DOI":"10.1001\/jama.2020.17598"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Li M. Yang Y. Xiong L. Jiang P. Wang J. Li C. (2023). Metabolism metabolites and macrophages in cancer. Journal of Hematology & Oncology 16(1) 80. https:\/\/doi.org\/10.1186\/s13045-023-01478-6","DOI":"10.1186\/s13045-023-01478-6"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Li W. Wu F. Zhao S. Shi P. Wang S. Cui D. (2022). Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine & Growth Factor Reviews 67 49\u201357. https:\/\/doi.org\/10.1016\/j.cytogfr.2022.07.004","DOI":"10.1016\/j.cytogfr.2022.07.004"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Liu D. Song Z. Wang X. Ouyang L. (2020). Ubiquitin C-terminal hydrolase L5 (UCHL5) accelerates the growth of endometrial cancer via activating the Wnt\/beta-catenin signaling pathway. Frontiers in Oncology 10 Article 865. https:\/\/doi.org\/10.3389\/fonc.2020.00865","DOI":"10.3389\/fonc.2020.00865"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Liu R. Zhu G. Sun Y. Li M. Hu Z. Cao P. .\u2004.\u2004.Chen J. (2023). Neutrophil infiltration associated genes on the prognosis and tumor immune microenvironment of lung adenocarcinoma. Frontiers in Immunology 14 Article 1304529. https:\/\/doi.org\/10.3389\/fimmu.2023.1304529","DOI":"10.3389\/fimmu.2023.1304529"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Maeda S. Sakai K. Kaji K. Iio A. Nakazawa M. Motegi T. .\u2004.\u2004.Momoi Y. (2022). Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. Scientific Reports 12(1) 4. https:\/\/doi.org\/10.1038\/s41598-021-04229-0","DOI":"10.1038\/s41598-021-04229-0"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Maeser D. Gruener R. F. Huang R. S. (2021). OncoPredict: An R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings in Bioinformatics 22(6) bbab260. https:\/\/doi.org\/10.1093\/bib\/bbab260","DOI":"10.1093\/bib\/bbab260"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Mayakonda A. Lin D. C. Assenov Y. Plass C. Koeffler H. P. (2018). Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Research 28(11) 1747\u20131756. https:\/\/doi.org\/10.1101\/gr.239244.118","DOI":"10.1101\/gr.239244.118"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Mu Y. Sun D. (2018). Lapatinib a dual inhibitor of epidermal growth factor receptor (EGFR) and HER-2 enhances radiosensitivity in mouse bladder tumor line-2 (MBT-2) cells in vitro and in vivo. Medical Science Monitor 24 5811\u20135819. https:\/\/doi.org\/10.12659\/MSM.909865","DOI":"10.12659\/MSM.909865"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Park J. Cho J. Song E. J. (2020). Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Archives of Pharmacal Research 43(11) 1144\u20131161. https:\/\/doi.org\/10.1007\/s12272-020-01281-8","DOI":"10.1007\/s12272-020-01281-8"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Qi G. Li L. (2020). LncRNA TTN-AS1 promotes progression of non-small cell lung cancer via regulating miR-491-5p\/ZNF503 axis. OncoTargets and Therapy 13 6361\u20136371. https:\/\/doi.org\/10.2147\/OTT.S238890","DOI":"10.2147\/OTT.S238890"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Qin D. Zhang Y. Shu P. Lei Y. Li X. Wang Y. (2024). Targeting tumor-infiltrating tregs for improved antitumor responses. Frontiers in Immunology 15 Article 1325946. https:\/\/doi.org\/10.3389\/fimmu.2024.1325946","DOI":"10.3389\/fimmu.2024.1325946"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Qiu C. Shi W. Wu H. Zou S. Li J. Wang D. .\u2004.\u2004.Geng H. (2021). Identification of molecular subtypes and a prognostic signature based on inflammation-related genes in colon adenocarcinoma. Frontiers in Immunology 12 Article 769685. https:\/\/doi.org\/10.3389\/fimmu.2021.769685","DOI":"10.3389\/fimmu.2021.769685"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Richters A. Aben K. K. H. Kiemeney L. (2020). The global burden of urinary bladder cancer: An update. World Journal of Urology 38(8) 1895\u20131904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4","DOI":"10.1007\/s00345-019-02984-4"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Robertson A. G. Meghani K. Cooley L. F. McLaughlin K. A. Fall L. A. Yu Y. .\u2004.\u2004.Meeks J. J. (2023). Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature Communications 14(1) 2126. https:\/\/doi.org\/10.1038\/s41467-023-37568-9","DOI":"10.1038\/s41467-023-37568-9"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Sarno J. Domizi P. Liu Y. Merchant M. Pedersen C. B. Jedoui D. .\u2004.\u2004.Davis K. L. (2023). Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia. Nature Communications 14(1) 2935. https:\/\/doi.org\/10.1038\/s41467-023-38456-y","DOI":"10.1038\/s41467-023-38456-y"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Sawant D. V. Yano H. Chikina M. Zhang Q. Liao M. Liu C. .\u2004.\u2004.Vignali D. A. A. (2019). Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nature Immunology 20(6) 724\u2013735. https:\/\/doi.org\/10.1038\/s41590-019-0346-9","DOI":"10.1038\/s41590-019-0346-9"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Shi Y. Wang Y. Dong H. Niu K. Zhang W. Feng K. .\u2004.\u2004.Zhang Y. (2023). Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: Novel perspective to mRNA vaccines and personalized immunotherapy. Apoptosis 28(9\u201310) 1423\u20131435. https:\/\/doi.org\/10.1007\/s10495-023-01868-8","DOI":"10.1007\/s10495-023-01868-8"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","unstructured":"Tornesello M. L. (2025). TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review). International Journal of Molecular Medicine 55(1). https:\/\/doi.org\/10.3892\/ijmm.2024.5448","DOI":"10.3892\/ijmm.2024.5448"},{"key":"e_1_3_2_45_1","unstructured":"Tumor Immune Dysfunction and Exclusion. (n.d.). http:\/\/tide.dfci.harvard.edu\/"},{"key":"e_1_3_2_46_1","doi-asserted-by":"crossref","unstructured":"van Hoogstraten L. M. C. Vrieling A. van der Heijden A. G. Kogevinas M. Richters A. Kiemeney L. A. (2023). Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice. Nature Reviews Clinical Oncology 20(5) 287\u2013304. https:\/\/doi.org\/10.1038\/s41571-023-00744-3","DOI":"10.1038\/s41571-023-00744-3"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","unstructured":"Varchulova Novakova Z. Kuniakova M. Ziaran S. Harsanyi S. (2023). Molecular biomarkers of bladder cancer: A mini-review. Physiological Research 72(S3) S247\u2013S256. https:\/\/doi.org\/10.33549\/physiolres.935187","DOI":"10.33549\/physiolres.935187"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"Wang J. Li J. Zhang L. Qin Y. Zhang F. Hu R. .\u2004.\u2004.Zhang X. (2021). Comprehensive analysis of ubiquitin-proteasome system genes related to prognosis and immunosuppression in head and neck squamous cell carcinoma. Aging (Albany NY) 13(16) 20277\u201320301. https:\/\/doi.org\/10.18632\/aging.203411","DOI":"10.18632\/aging.203411"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","unstructured":"Wang M. Chen X. Tan P. Wang Y. Pan X. Lin T. .\u2004.\u2004.Chen C. (2022). Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell 40(9) 1044\u20131059.e1048. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.010","DOI":"10.1016\/j.ccell.2022.08.010"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","unstructured":"Wang Z. Kang W. Li O. Qi F. Wang J. You Y. .\u2004.\u2004.Liu H. M. (2021). Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B 11(3) 694\u2013707. https:\/\/doi.org\/10.1016\/j.apsb.2020.11.005","DOI":"10.1016\/j.apsb.2020.11.005"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","unstructured":"Wu G. Wang F. Li K. Li S. Zhao C. Fan C. Wang J. (2019). Significance of TP53 mutation in bladder cancer disease progression and drug selection. PeerJ 7 Article e8261. https:\/\/doi.org\/10.7717\/peerj.8261","DOI":"10.7717\/peerj.8261"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","unstructured":"Xiao H. Huang W. Li Y. Zhang R. Yang L. (2021). Targeting long non-coding RNA TTN-AS1 suppresses bladder cancer progression. Frontiers in Genetics 12 Article 704712. https:\/\/doi.org\/10.3389\/fgene.2021.704712","DOI":"10.3389\/fgene.2021.704712"},{"key":"e_1_3_2_53_1","doi-asserted-by":"crossref","unstructured":"Xu D. Wang Y. Chen Y. Zheng J. (2023). Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes. Cancer Immunology Immunotherapy 72(3) 647\u2013664. https:\/\/doi.org\/10.1007\/s00262-022-03269-3","DOI":"10.1007\/s00262-022-03269-3"},{"key":"e_1_3_2_54_1","doi-asserted-by":"crossref","unstructured":"Xu F. Xu X. Deng H. Yu Z. Huang J. Deng L. Chao H. (2024). The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression. Translational Oncology 49 102104. https:\/\/doi.org\/10.1016\/j.tranon.2024.102104","DOI":"10.1016\/j.tranon.2024.102104"},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","unstructured":"Yerlikaya A. Kanbur E. Stanley B. A. Tumer E. (2021). The ubiquitin-proteasome pathway and epigenetic modifications in cancer. Anti-Cancer Agents in Medicinal Chemistry 21(1) 20\u201332. https:\/\/doi.org\/10.2174\/1871520620666200811114159","DOI":"10.2174\/1871520620666200811114159"},{"key":"e_1_3_2_56_1","doi-asserted-by":"crossref","unstructured":"Zhang L. Peng M. (2022). Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer. Frontiers in Immunology 13 Article 1030097. https:\/\/doi.org\/10.3389\/fimmu.2022.1030097","DOI":"10.3389\/fimmu.2022.1030097"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","unstructured":"Zhang Y. Zhang Z. (2020). The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology 17(8) 807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6","DOI":"10.1038\/s41423-020-0488-6"},{"key":"e_1_3_2_58_1","doi-asserted-by":"crossref","unstructured":"Zhao P. Zhen H. Zhao H. Huang Y. Cao B. (2023). Identification of hub genes and potential molecular mechanisms related to radiotherapy sensitivity in rectal cancer based on multiple datasets. Journal of Translational Medicine 21(1) 176. https:\/\/doi.org\/10.1186\/s12967-023-04029-2","DOI":"10.1186\/s12967-023-04029-2"},{"key":"#cr-split#-e_1_3_2_59_1.1","doi-asserted-by":"crossref","unstructured":"Zhao Y. Huang T. Huang P. (2022). Integrated analysis of tumor mutation burden and immune infiltrates in hepatocellular carcinoma. Diagnostics (Basel) 12","DOI":"10.3390\/diagnostics12081918"},{"key":"#cr-split#-e_1_3_2_59_1.2","doi-asserted-by":"crossref","unstructured":"(8) 1918. https:\/\/doi.org\/10.3390\/diagnostics12081918","DOI":"10.3390\/diagnostics12081918"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","unstructured":"Zhu G. Pei L. Li Y. Gou X. (2020). EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging (Albany NY) 12(3) 2132\u20132141. https:\/\/doi.org\/10.18632\/aging.102728","DOI":"10.18632\/aging.102728"}],"container-title":["American Journal of Men's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251410519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15579883251410519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251410519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:28:31Z","timestamp":1777505311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15579883251410519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/15579883251410519"],"URL":"https:\/\/doi.org\/10.1177\/15579883251410519","relation":{},"ISSN":["1557-9883","1557-9891"],"issn-type":[{"value":"1557-9883","type":"print"},{"value":"1557-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"15579883251410519"}}